Aeterna Zentaris Appoints Leslie Auld as Chief Financial Officer
September 25 2018 - 8:00AM
Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZS), a
biopharmaceutical company engaged in developing and commercializing
pharmaceutical products, today announced the appointment of Leslie
Auld as Senior Vice President, Chief Financial Officer.
Ms. Auld has over twenty-five years of
accounting, finance and pharmaceutical industry experience, with
increasingly senior roles at PricewaterhouseCoopers, Helix
BioPharma Corp., Luminex Diagnostics (formerly TM BioScience
Corp.), Attwell Capital Inc. (formerly Fralex Therapeutics) and
GeneNews Limited. A Chartered Professional Accountant, Ms. Auld
graduated with an Honours Bachelor of Science, Pharmacology &
Toxicology from the University of Western Ontario, and has a Master
of Business Administration degree from the University of
Toronto.
Ms. Auld is replacing James Clavijo, who is
leaving Aeterna Zentaris to pursue other interests.
“We are thankful to James for the important role
he played with us while we implemented the first stage of our
licensing arrangements with Strongbridge Biopharma plc,” stated
Michael V. Ward, President and Chief Executive Officer for Aeterna
Zentaris. “Now, having successfully launched Macrilen™
(macimorelin) this summer, we are excited to have been able to
attract someone as accomplished and experienced as Leslie to our
senior executive team.”
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a biopharmaceutical company focused on
developing and commercializing, principally through out-licensing
arrangements, Macrilen™ (macimorelin), an oral ghrelin receptor
agonist, to be administered in the diagnosis of patients with adult
growth hormone deficiency. Aeterna Zentaris has licensed Macrilen™
(macimorelin) to Strongbridge Biopharma plc in the United States
and Canada. For more information, visit www.zentaris.com.
Forward-Looking StatementsThis press release
contains forward-looking statements (as defined by applicable
securities legislation) made pursuant to the safe-harbor provision
of the U.S. Securities Litigation Reform Act of 1995, which reflect
our current expectations regarding future events. Forward-looking
statements may include, but are not limited to statements preceded
by, followed by, or that include the words "will," "expects,"
"believes," "intends," "would," "could," "may," "anticipates," and
similar terms that relate to future events, performance, or our
results. Forward-looking statements involve known and unknown risks
and uncertainties, including those discussed in this press release
and in our Annual Report on Form 20-F, under the caption "Key
Information - Risk Factors" filed with the relevant Canadian
securities regulatory authorities in lieu of an annual information
form and with the U.S. Securities and Exchange Commission ("SEC").
Known and unknown risks and uncertainties could cause our actual
results to differ materially from those in forward-looking
statements. Such risks and uncertainties include, among others, our
now heavy dependence on the success of Macrilen™ (macimorelin) and
related out-licensing arrangements and the continued availability
of funds and resources to successfully launch the product, the
ability of Aeterna Zentaris to enter into out-licensing,
development, manufacturing and marketing and distribution
agreements with other pharmaceutical companies and keep such
agreements in effect, reliance on third parties for the
manufacturing and commercialization of our product candidates,
potential disputes with third parties, leading to delays in or
termination of the manufacturing, development, out-licensing or
commercialization of our product candidates, or resulting in
significant litigation or arbitration, and, more generally,
uncertainties related to the regulatory process, our ability to
efficiently commercialize or out-license Macrilen™ (macimorelin),
the degree of market acceptance of Macrilen™ (macimorelin), our
ability to obtain necessary approvals from the relevant regulatory
authorities to enable us to use the desired brand names for our
products, the impact of securities class action litigation, the
litigation involving two of our former officers, litigation brought
by Cogas Consulting, LLC, or other litigation, on our cash flow,
results of operations and financial position; any evaluation of
potential strategic alternatives to maximize potential future
growth and stakeholder value may not result in any such alternative
being pursued, and even if pursued, may not result in the
anticipated benefits, our ability to take advantage of business
opportunities in the pharmaceutical industry, our ability to
protect our intellectual property, the potential of liability
arising from shareholder lawsuits and general changes in economic
conditions. Investors should consult our quarterly and annual
filings with the Canadian and U.S. securities commissions for
additional information on risks reliance on these forward-looking
statements. We disclaim any obligation to update any such factors
or to publicly announce any revisions to any of the forward-looking
statements contained herein to reflect future results, events or
developments, unless required to do so by a governmental authority
or applicable law.
Contacts: Michael V. WardChief
Executive OfficerAeterna Zentaris Inc. IR@aezsinc.com
843-900-3201
Susan ReillyPresidentReilly
Connectsusan.reilly@reillyconnect.com312-600-6783
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024